Form 4: DiaMedica Director Receives Stock Option Grant

Director Randall Michael Giuffre was granted 40,412 stock options in DiaMedica Therapeutics Inc. on June 1, 2026.

Summary

• Director Randall Michael Giuffre received a grant of 40,412 stock options.
• The options have an exercise price of $5.84 per share.
• The grant is scheduled to vest in four equal quarterly installments.
• The options expire on June 1, 2036.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in terms of immediate market impact.

Positives

• Alignment of director interests with shareholders through equity-based compensation.

Negatives

• The grant results in potential future dilution for existing shareholders.

Risks

• Market volatility affecting the value of the granted options.
• Potential for future dilution of equity.

Future Outlook

The options vest in four equal quarterly installments, indicating a long-term retention and incentive strategy for the director.

Industry Context

StockSavvy.ai notes that equity grants to directors are standard corporate governance practices in the biotechnology sector to ensure long-term alignment with company performance and shareholder value.

Comparison to Industry Standards

• The use of quarterly vesting schedules is consistent with standard industry practices for director compensation to encourage long-term commitment.

Corporate Governance

Stakeholder Impact

• Shareholders may experience minor dilution upon the exercise of these options.

Next Steps

• Vesting of options in four equal quarterly installments.

Key Dates

Keywords

DiaMedica Therapeutics, DMAC, Stock Options, Director Compensation, SEC Form 4, Equity Grant